ArticleProceedings of the National Academy of Sciences of the United States of America2018
Coamplification of
Open access · bronzeAbstract read
In one paragraph
Article in Proceedings of the National Academy of Sciences of the United States of America, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
1.3field-weighted citation impact, top 16% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 30 citations in OpenAlex.
- MicroRNAs in Breast Cancer: Biological Functions and Technologies for Experimental and Therapeutic Applications.Cancers · 2026Review
- Identification of novel exosomal miRNAs and their role in diagnosis and prognosis of triple negative breast cancer.BMC cancer · 2026Article
- Non-coding RNAs as regulators of chromosomal instability in breast cancer.Frontiers in oncology · 2026Review
- Targeting SUMOylation promotes cBAF complex stabilization and disruption of the SS18::SSX transcriptome in synovial sarcoma.Nature communications · 2025Article
- A new era of cancer immunotherapy: vaccines and miRNAs.Cancer immunology, immunotherapy : CII · 2025Review
- Non-coding RNAs as novel biomarkers and therapeutic targets in breast cancer.Oncology reviews · 2025Review
- Case report: Near-complete response to neratinib-based treatment in HR-positiveFrontiers in oncology · 2024Article
- MiRNA-Based Therapies for Lung Cancer: Opportunities and Challenges?Biomolecules · 2023Review
- The Role of Different Types of microRNA in the Pathogenesis of Breast and Prostate Cancer.International journal of molecular sciences · 2023Review
- miR-216b-5p promotes late apoptosis/necroptosis in trastuzumab-resistant SK-BR-3 cells.Turkish journal of biology = Turk biyoloji dergisi · 2023Article
- Article
- The Role of MicroRNAs in HER2-Positive Breast Cancer: Where We Are and Future Prospective.Cancers · 2022Review
- MCL-1 is a clinically targetable vulnerability in breast cancer.Cell cycle (Georgetown, Tex.) · 2022Review
- Breast Cancer Subtype-Specific miRNAs: Networks, Impacts, and the Potential for Intervention.Biomedicines · 2022Review
- Mir-4728 is a Valuable Biomarker for Diagnostic and Prognostic Assessment of HER2-Positive Breast Cancer.Frontiers in molecular biosciences · 2022Article
- Splice and Dice: Intronic microRNAs, Splicing and Cancer.Biomedicines · 2021Review
- Article
- Targeting MCL-1 in cancer: current status and perspectives.Journal of hematology & oncology · 2021Review
- Targeting transcription of MCL-1 sensitizes HER2-amplified breast cancers to HER2 inhibitors.Cell death & disease · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 9 institutions in 2 countries.
Konstantinos V FlorosDepartment of Oral and Craniofacial Molecular Biology, Philips Institute for Oral Health Research, VCU School of Dentistry and Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298.
Timothy L LochmannDepartment of Oral and Craniofacial Molecular Biology, Philips Institute for Oral Health Research, VCU School of Dentistry and Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298.ORCID 0000-0002-3368-6067
Bin HuDepartment of Pathology, Virginia Commonwealth University School of Medicine, Richmond, VA 23220.
Carles MonterrubioDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065.
Mark T HughesDepartment of Oral and Craniofacial Molecular Biology, Philips Institute for Oral Health Research, VCU School of Dentistry and Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298.
Jason D WellsDepartment of Molecular & Systems Biology, Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Lebanon, NH 03756.
Cristina Bernadó MoralesPreclinical Research Program, Vall d'Hebron Institute of Oncology, 08035 Barcelona, Spain.
Maninderjit S GhotraDepartment of Oral and Craniofacial Molecular Biology, Philips Institute for Oral Health Research, VCU School of Dentistry and Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298.
Carlotta CostaDepartment of Medicine, Massachusetts General Hospital, Cancer Center and Harvard Medical School, Boston, MA 02129.
Andrew J SouersOncology Discovery Department, AbbVie Inc., North Chicago, IL 60064.
Sosipatros A BoikosDivision of Hematology, Oncology and Palliative Care, Virginia Commonwealth University, Massey Cancer Center, Richmond, VA 23298.
Joel D LeversonOncology Development Department, AbbVie Inc., North Chicago, IL 60064.
Ming TanDepartment of Oncological Sciences, Mitchell Cancer Institute, University of South Alabama, Mobile, AL 36604.
Violeta SerraCentro de Investigación Biomédica en Red en Oncologia (CIBERONC), 08035 Barcelona, Spain.
Jennifer E KoblinskiDepartment of Pathology, Virginia Commonwealth University School of Medicine, Richmond, VA 23220.
Joaquin ArribasPreclinical Research Program, Vall d'Hebron Institute of Oncology, 08035 Barcelona, Spain.
Aleix PratTranslational Genomics and Targeted Therapeutics in Solid Tumors, Institut D'Investigacions Biomèdiques August Pi i Sunyer, 08036 Barcelona, Spain.
Laia ParéTranslational Genomics and Targeted Therapeutics in Solid Tumors, Institut D'Investigacions Biomèdiques August Pi i Sunyer, 08036 Barcelona, Spain.
Todd W MillerDepartment of Molecular & Systems Biology, Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Lebanon, NH 03756.
Mikhail G DozmorovDepartment of Biostatistics, Virginia Commonwealth University, Richmond, VA 23298-0032.ORCID 0000-0002-0086-8358
Hisashi HaradaDepartment of Oral and Craniofacial Molecular Biology, Philips Institute for Oral Health Research, VCU School of Dentistry and Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298.
Brad E WindleDepartment of Oral and Craniofacial Molecular Biology, Philips Institute for Oral Health Research, VCU School of Dentistry and Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298.
Maurizio ScaltritiDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065.
Anthony C FaberDepartment of Oral and Craniofacial Molecular Biology, Philips Institute for Oral Health Research, VCU School of Dentistry and Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298; acfaber@vcu.edu.
Virginia Commonwealth University · USAbbVie (United States) · USDartmouth College · USMemorial Sloan Kettering Cancer Center · USCentro de Investigación Biomédica en Red de Cáncer · ESHarvard University · USInstitució Catalana de Recerca i Estudis Avançats · ESUSA Mitchell Cancer Institute · USVall d'Hebron Institut de Recerca · ES
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MVirus Vector Shared ResourceP30CA016059 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI Keri R Maher · 1985 to 2026
$51.0MA precision medicine basis for estrogen therapy for advanced breast cancerR01CA200994 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI Todd W. Miller · 2017 to 2026
$3.7MTiming is everything: applications in precision oncology for ER+ breast cancerR01CA211869 · NCI · DARTMOUTH COLLEGE · PI MILLER, TODD W. · 2017 to 2021
$2.1MAssessing BIM expression as a cause and marker for resistance to targeted therapiK22CA175276 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI FABER, ANTHONY CHARLES · 2014 to 2016
$573kThe possible role of the novel Akt 3 R247C mutation in opposing to anti-HER2 therR03CA187094 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SCALTRITI, MAURIZIO · 2014 to 2015
$176kNCI NIH HHS K22 CA175276NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA016059NCI NIH HHS R01 CA200994NCI NIH HHS R01 CA211869NCI NIH HHS R03 CA187094
Abstract
PubMed holds no abstract for this paper.
Indexed as
Antineoplastic AgentsApoptosisBreast NeoplasmsCell Line, TumorDrug Resistance, NeoplasmErb-b2 Receptor Tyrosine KinasesFemaleGene AmplificationHumansMicroRNAsProtein Kinase InhibitorsProto-Oncogene Proteins c-bcl-2Antineoplastic AgentsERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesMicroRNAsMIRN4728 microRNA, humanPMAIP1 protein, humanProtein Kinase InhibitorsProto-Oncogene Proteins c-bcl-2apoptosisHER2 amplificationMCL-1 inhibitorNOXAtargeted therapies
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.